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Abstract
Chronic rhinosinusitis (CRS) is a multifactorial disease of the upper airways with
a high prevalence (approximately 11%) in the general population. Different
immune and inflammatory mechanisms are involved in its pathogenesis. Altera-
tions in the arachidonic acid pathway (leading to an imbalanced production of
eicosanoids) have been linked to the pathophysiology of different diseases espe-
cially nasal polyposis, asthma, and aspirin-exacerbated respiratory disease. Fur-
thermore, viral and bacterial infections have been identified as important factors
amplifying the pro-inflammatory reactions in these pathologies. This review sum-
marizes the impact of an imbalance in the eicosanoid pathway and the effect of
Staphylococcus aureus enterotoxins on the regulation of the pro-inflammatory
network in CRS and their translation into disease severity.
Chronic rhinosinusitis (CRS) is a multifactorial inflamma-
tory disease of the nasal and paranasal sinuses with a high
impact on the quality of life (1, 2). CRS may or may
not be accompanied by polyp formation and often occur in
combination with other airway pathologies like asthma,
allergy, aspirin intolerance, and cystic fibrosis (3). Although a
considerable amount of research has been dedicated to
the study of its pathogenesis, the inflammatory mechanisms
underlying the disease remain unclear.
Bacterial superantigens (SAgs) are recently discovered
players in the regulation of the inflammatory process in air-
way inflammatory diseases (4–6). Staphylococcus aureus
(S. aureus), a pathogenic Gram-positive bacteria, often colo-
nize the human skin, the upper respiratory tract, and the
intestinal tract. This microorganism has the capability of
producing and releasing enterotoxins with superantigenic
activity. These so-called staphylococcal SAgs have strong
immune-modulatory and pro-inflammatory effects able to
modify the functions of T and B cells, eosinophils, inflamma-
tory and structural cells. Staphylococcal enterotoxins (SEs)
have been shown to influence type 2 T-helper cell-polariza-
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tion, eosinophilic inflammation, and polyclonal IgE produc-
tion and hence to contribute to the amplification and mainte-
nance (chronicity) of the inflammatory mechanisms operating
in airway diseases (4).
In the last two decades, it has been demonstrated that
alterations in eicosanoid synthesis play an important role in
airway inflammatory conditions like rhinosinusitis, nasal
polyposis, allergic rhinitis, and asthma. This imbalance is
characterized by increased synthesis of cysteinyl leukotrienes
(CysLTs) by inflamed tissue in contrast to slightly increased
prostaglandin E2 (PGE2) release when compared with nor-
mal tissue, which correlates with the inflammatory pattern
and severity of the diseases. In this review, we discuss the
impact of imbalance in the eicosanoid pathway and the effect
of S. aureus enterotoxins in the regulation of the pro-inflam-
matory network in CRS, and how they contribute to the
severity of the disease.
Eicosanoid biosynthetic pathway
Eicosanoids are inflammatory mediators that regulate crucial
homeostatic functions such as inflammation, immunity, and
messenger networks in the central nervous system (7). Their
synthesis starts when the cell activated by mechanical trauma,
cytokines, pathogens, or other stimuli triggers the release of
membrane-bound fatty acids that are then metabolized via
the cyclooxygenase (COX) and/or the lipoxygenase pathways
(7) (Fig. 1).
The COX pathway involves the COX-1 and COX-2
enzymes that convert the arachidonic acid (AA) to prostacyc-
lins (PGI2), prostaglandins (PGD2, PGE2, PGF2a), and
thromboxanes (TXA2, TXB2) (8). COX-1 is mainly expressed
constitutively, and COX-1-dependent prostaglandins are
thought to control a number of physiological ‘homeostatic’
functions (8). The expression of COX-2, in contrast, seems to
be inducible in response to pro-inflammatory stimuli, and
COX-2-dependent prostaglandins may have both pro- and
anti-inflammatory actions (8).
The lipoxygenase pathway involves the enzymes ALOX5
leading to the production of leukotrienes (LTs) and the
ALOX15/12 for the synthesis of lipoxins (LXs). The LTs
group comprises leukotriene B4 (LTB4) and CysLTs LTC4,
LTD4, and LTE4 (9). LTB4 is a potent neutrophil chemoattr-
actant and regulates mainly leukocyte activation, migration,
and apoptosis by binding to the BLT1 and BLT2 receptors
(9). CysLTs have a potent bronchoconstriction activity
and act by binding to the cysteinyl leukotriene receptor 1
(CysLT1) and CysLT2 receptors (10).
Lipoxins (LXA4 and LXB4) have been identified as endog-
enous ‘braking signals’ with potent anti-inflammatory and
pro-resolving actions (11). Their synthesis occurs via three
transcellular routes: the first involves the generation of LTA4
Figure 1 Arachidonic acid cascade leading to the formation of cysteinyl leukotrienes, prostaglandins, thromboxanes, lipoxins, and aspirin-
triggered lipoxins.
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by ALOX5, present in cells of myeloid lineage, which is
taken up by platelets where it is metabolized to form LXA4
by the enzyme ALOX12 (12). A second route involves the
generation of 15-Hydroxyeicosatetraenoic acid (15(S)-HETE)
by epithelial- and/or monocyte-derived ALOX15 that serves
as a substrate for ALOX5 in neutrophils to produce LXA4
and LXB4 (12). The third and additional route is the so-
called aspirin-triggered 15-epi-LX (ATLXs) pathway. In this
pathway, intake of aspirin irreversibly inhibits COX-1 and
acetylates COX-2 enzyme resulting in the formation of 15(S)-
HETE, which is then transformed by leukocyte-derived
ALOX5 to 15-epi-LXA4 or 15-epi-LXB4 (13). Both LXA4
and 15-epi-LXA4 bind and activate lipoxin receptors mostly
leading to the resolution of inflammation (13).
Implications of eicosanoid imbalance on chronic sinus
diseases
The imbalance of the eicosanoid pathway in paranasal sinus
diseases and especially nasal polyps has been demonstrated
by several studies.
Leukotrienes
Cysteinyl leukotrienes are potent inducers of airway inflam-
mation by promoting inflammatory cell (mainly eosinophils)
recruitment and activation (14). They also influence airway
remodeling by inducing smooth muscle cell and epithelial cell
proliferation (15). In inflamed nasal mucosa, LTs promote
nasal congestion and edema by inducing vascular leakage
and vasodilatation (16). Concentrations of ALOX5, leukotri-
ene synthase (LTC4S), and CysLT1 receptor are significantly
increased in nasal polyp tissue from chronic rhinosinusitis
with nasal polyp patients (CRSwNP) compared to chronic
rhinosinusitis without polyps (CRSsNP) and control subjects
(17). CysLTs levels in patients with CRSwNP positively
correlate with the number of activated eosinophils as well as
with eosinophil cationic protein (ECP), IL-5, and IL-5Ra
concentrations (17). Activated eosinophils infiltrating the
nasal polyp tissue are the probable major biosynthetic source
of CysLTs and CysLT1 receptor (18, 19). Although the phys-
iological mechanisms regulating the biosynthesis of CysLTs
by these cells are not clear yet, it is known that ‘activated’
eosinophils produce high quantities of LTC4 after priming
with factors such as eotaxin, platelet-activating factor (PAF),
and IL-5 (14). Consequently, the up-regulation of LTs acts
as a paracrine and autocrine mechanism for chemotaxis and
survival of eosinophils, a mechanism likely to operate in
CRSwNP.
Controversial results regarding the regulation of LTB4 and
its receptors (BLT1 and BLT2) have been reported. In a
study in 2006, we did not find any differences in the protein
levels of LTB4 and mRNA for BLT1 and BLT2 between
CRSsNP, CRSwNP groups, and normal nasal mucosa
groups (18). Another study, however, reported that levels of
LTB4 are increased in CRSwNP patients with allergy in com-
parison with nonallergic and control subjects (16). The rea-
son for this discrepancy may be due to differences in the
study groups or in the complexity of the LTB4 pathway. It
could be that synthesis of LTB4 in CRS and especially in
CRSwNP greatly depends on the balance between the differ-
ent inflammatory cells present in the tissue and the concen-
tration of the enzymes involved in its synthesis in each of
these cell types.
Prostaglandins
Roca-Ferrer et al. (20) reported for the first time that nasal
polyp tissue has a diminished capacity to produce PGE2 and
up-regulate COX-1, COX-2, and prostaglandin E receptor
EP2 under pro-inflammatory conditions. Further, in an
attempt to find a link between PG pathway and eosinophilic
inflammation observed in CRSwNP, we observed that mRNA
expression of prostaglandin E receptors EP1 and EP3 is down-
regulated in CRSwNP tissue in contrast to EP2 and EP4 recep-
tors that are significantly increased in both CRS groups when
compared with control tissue (21). Of interest, levels of EP2
and EP4 receptors did not correlate with eosinophil numbers
or eosinophil activation markers, in contrast to PGE2 which
was down-regulated and inversely correlated with eosinophilic
inflammation in CRSwNP patients. Expression of EP2 and
EP4 receptors in eosinophils from asthmatic patients was pre-
viously reported by Mita et al. (22). However, in that study,
EP4 was suggested as the only functional receptor in these cells
and its signaling might be dependent on the level of exposure
to PGE2 (22). The impact of PGE2 and its receptors on eosino-
phil function in CRS is still unclear. PGE2 attenuated the syn-
thesis of LTC4 by eosinophils isolated from normal and atopic
individuals (23). However, Peacock et al., (24) showed that
PGE2 inhibited eosinophil apoptosis, prolonging their survival
and activation. These data suggest that effect of PGE2 in CRS
may depend on the regulation of its receptors, inflammatory
millieu, and more importantly the contribution of other cells
as explained below.
Fibroblasts are an important source of PGs in the airways;
however, controversial data in CRswNP have been reported.
Liu et al. (25) found that nasal polyp fibroblasts (NPFs) are
able to produce significantly higher amounts of constitutive
COX-2 mRNAs compared to fibroblasts from nasal inferior
turbinate; Roca-Ferrer et al., (20) however, showed that
NPFs have significantly lower levels of COX-1 and COX-2
mRNA and were unable to induce their expression after
IL-1b stimulation. Of interest, both findings can be extrapo-
lated to the inflammatory pattern observed in nasal polypo-
sis. It has been suggested that up-regulation of COX-2
expression by fibroblasts may contribute to nasal polyp
development by promoting vascular dilatation (25). Further-
more, PGE2 may also influence tissue remodeling by inducing
mucin secretion, a main feature of CRSwNP (26). However,
an important aspect to consider is that COX-2 may stimulate
tissue remodeling by increasing TGF-b and collagen synthe-
sis, but these two molecules are down-regulated in nasal
polyp tissue (27). Analyzing altogether, one might reasonably
question the role of PGE2 in the pathogenesis of nasal polyp-
osis. It does not seem possible to give an answer at this stage
but it appears that regulation of this pathway greatly
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depends on the individual contribution of the different cell
types and the cytokine milieu that surround them.
Finally, PGD2, one of the major mast cell–derived prosta-
noids, being released during the early phase of allergic reac-
tions, is highly secreted after IgE stimulation of nasal polyp
tissue (28). Okano et al. (29) showed that hematopoietic
prostaglandin D synthase (hPGDS) and microsomal prosta-
glandin E synthase-1 (m-PGES-1) display an opposite regula-
tion in CRSwNP. In that study, transcript levels of hPGDS
were increased in CRSwNP compared to CRSsNP and
healthy subjects and positively correlated with the clinical
disease severity and with the number of activated eosinophils
(29). However, m-PGES-1 was down-regulated in CRSwNP
and inversely correlated with the severity of sinusitis (29).
On the other hand, distribution and expression of PGD2
receptors also seem to be counter-regulated. DP1 receptor
expression is increased in tissue-infiltrating inflammatory and
constitutive cells in CRSwNP compared to noninflamed nasal
mucosa (30). CRTH2 in contrast was mainly localized in
inflammatory cells (eosinophils and T cells) and showed two
distinct expression patterns. One pattern showed increased
expression of the receptor in CRSsNP, and a second pattern
demonstrated low levels in the more severe cases (CRSwNP)
and an inverse correlation with IL-5 and eotaxin levels (30).
Further, in the same study, incubation of nasal polyp tissue
explants with PGD2 significantly reduced CRTH2 mRNA,
suggesting that different to DP1, transcriptional regulation of
this receptor may be linked to a negative feedback mecha-
nism orchestrated by PGD2 and probably eosinophil-associ-
ated mediators (30). We later demonstrated that PGD2
released after 30-min stimulation of nasal polyp tissue
explants with IgE promotes the migration of TH2 cells
through a CRTH2-dependent mechanism (31). However, IgE
increased the transcript levels of both DP1 and CRTH2
receptors in the tissue. These discrepancies regarding CRTH2
response between the studies may be due to differences in the
target cell type and/or experimental conditions. In addition,
it could be that during the early phase of the allergic reac-
tion, up-regulation of DP1 and CRTH2 receptors is needed
in order to recruit inflammatory cells to the tissue. Once the
late phase is started, where cytokines and other mediators
are synthesized, a decrease in the expression of the receptor
will be needed to control the local inflammatory reaction, as
suggested by Yamamoto (30).
Lipoxins
Several studies have demonstrated that the progression of
inflammation in several airway chronic diseases is associated
with deficiencies in lipoxin production and/or an imbalance
between pro-inflammatory eicosanoids and lipoxins (32).
However, knowledge on their expression and role in upper
airway diseases is limited. ALOX15 mRNA and LXA4 levels
are up-regulated in CRSwNP patients compared to control
subjects (17). In addition, ALOX15 was localized in the epi-
thelium and subepithelium of CRS and even more in nasal
polyp tissues (data not published), confirming its expression
in the nasal mucosa. This positive immunostaining correlated
with the amount of activated eosinophils infiltrating the
nasal polyp epithelium and mucosa, suggesting that the
increased levels of LXA4 may be related to a transcellular
interaction between eosinophils and tissue-resident cells, such
as cytokine-primed endothelial or epithelial cells. LXA4 may
influence cellular electrochemical properties by inducing chlo-
ride (Cl) secretion and cellular calcium (Ca2+) mobilization
(33). Intracellular Ca2+ plays a central role in epithelial cel-
lular function such as ion or protein secretion and cell tonic-
ity. Although not proven yet, this imbalance of sodium
(Na+)/Cl levels that alter epithelial permeability may lead
to the accumulation of extracellular fluid promoting edema
formation, a hallmark of nasal polyposis. In summary, this
points out that not the absolute amount of LXs but the bal-
ance with other pro-inflammatory molecules such as LTs
may be of great importance, and that these molecules may
play a crucial role via modifying cellular electrochemical and
physicochemical properties.
Eicosanoid imbalance in aspirin-exacerbated
respiratory disease
Aspirin-exacerbated respiratory disease (AERD) is a distinct
clinical syndrome of intractable inflammation of both upper
and lower respiratory tracts, which is characterized by
chronic eosinophilic rhinosinusitis with asthma, nasal polypo-
sis and hypersensitivity to aspirin and other nonsteroidal
anti-inflammatory drugs that inhibit COX-1 (34–36). The
hallmark of the disease is the precipitation of violent asth-
matic attacks (accompanied usually by nasal blockage and
ocular symptoms) by aspirin and other COX-1 inhibitors
(35). The prevalence of this syndrome in the general popula-
tion is of about 0.6–2.5%; however, it occurs in 4.3–21% of
patients with bronchial asthma and even more (15–40%)
in subjects with asthma and nasal polyposis (35). AERD
represents probably the most severe form of chronic sinusitis:
80–99% of patients have radiological changes in sinuses and
up to 60% suffer from nasal polyposis (35).
At the biochemical level, this syndrome is characterized by
profound alterations in eicosanoid biosynthesis, which consti-
tutes the basis of the COX theory of AERD (37). The
balance between pro-inflammatory acting CysLTs and PGs
(namely PGD2), anti-inflammatory PGs (namely PGE2), and
lipoxins is deregulated in AERD patients (38–40). Increased
production of CysLTs in these subjects is present at baseline
and is increased further following aspirin challenge, measur-
able in urine, nasal, bronchial lavages, and breath conden-
sates (39, 41). Furthermore, severity of reactions to aspirin is
linked to higher levels of urinary LTE4 and 9a11b-PGF2 (a
metabolite of PGD2) expression following aspirin challenge
(38). Nevertheless, the nasal mucosa and tissue of nasal pol-
yps may largely contribute to overall production of eicosa-
noids. In 1993, Kowalski et al. (42) reported an increase in
LT concentrations in nasal lavages from AERD subjects fol-
lowing nasal aspirin challenge, suggesting the link between
the release of these metabolites and the clinical symptoms
observed in these patients. In 1998, Andrzej Szczeklik from
the University of Cracow, Stephen T. Holgate from Univer-
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sity of Southampton, and Frank Austen from Harvard
Medical School discovered a marked overexpression of
baseline CysLTs in bronchoalveolar lavage (BAL) fluid of
AERD patients, which in turn correlated with the number of
LTC4 synthase-positive cells in the bronchial mucosa and
bronchial responsiveness to lysine-aspirin challenge (43).
Later, we confirmed that the levels of CysLTs and the
expression of ALOX5, LTC4S, and CysLT1 receptor are
significantly up-regulated in the nasal polyp tissue of AERD
patients and correlated with IL-5 and ECP concentrations
(17, 19).
The regulation of PG synthesis in the disease is more com-
plex. Levels of PGD2 metabolites are increased at baseline
and following aspirin challenge in AERD (38). On the other
hand, AERD patients respond with a diminished capacity to
produce anti-inflammatory acting PGE2 in both upper and
lower airways after bronchial aspirin challenge (44). Taking
this one step further, Picado et al., (45) showed that COX-2
mRNA levels and NF-jΒ activity are markedly lower in
nasal polyp tissue from AERD subjects. These findings were
corroborated by Kowalski et al. (46) who also demonstrated
that nasal polyp epithelial cells isolated from AERD patients
have a lower capacity to produce PGE2 than those from
non-AERD patients. Later, we demonstrated that COX-2
mRNA and PGE2 concentrations are indeed significantly
decreased in nasal polyp tissue from AERD patients and
inversely correlated with the degree of eosinophilic inflamma-
tion (17). In the bronchial compartment, however, the situa-
tion is different. The group of Corrigan et al. (47) found that
although concentrations of PGE2 in BAL were similar in
AERD and non-AERD patients, bronchial mucosa of
AERD subjects had reduced percentages of T cells, macro-
phages, mast cells, and neutrophils expressing the EP2 recep-
tor. Previously, Pierzchalska et al. (48, 49) showed that
human bronchial fibroblasts and epithelial cells from AERD
patients have low capacity to produce PGE2, and this was
linked to down-regulation of COX-1 protein. Surprisingly,
Sanak et al. (50) observed that oral aspirin challenge
decreased the systemic levels of two major PGE2 metabolites
only in the non-AERD group supporting the implication of a
COX-1-dependent or an alternative COX-2-PGE2 mechanism
in the pathogenesis of this disease, which is in line with the
fact that selective COX-2 inhibitor drugs are better tolerated
than those blocking COX-1 enzyme.
Finally, contributions of ALOX15 metabolites such as
lipoxins and 15(S)-HETE(s) in the pathogenesis of AERD
cannot be excluded. In 2000, Sanak et al. (51) demonstrated
for the first time that whole blood cells from asthmatic
patients have the capacity to generate both LXA4 and 15-
ATLXs, but that AERD patients display a lower biosynthetic
capacity than non-AERD subjects. This was later clinically
confirmed by Yamaguchi et al. (40) who demonstrated
decreased concentrations of both urinary 15-epi-LXA4 and
LXA4 in patients with AERD. In upper airways, nasal polyp
tissue from CRSwNP had higher concentrations of LXA4
when compared to healthy nasal mucosa but those levels
were decreased in patients with AERD (17). Results of the
study conducted in 2009 by Kuna et al. support this finding.
They demonstrated that nasal challenge with lysine-aspirin
induced the release of LTC4 but showed a decrease in LXA4
levels in AERD patients in contrast to non-AERD subjects
who responded with no change in LTC4 levels and an
increase in LXA4 (52). Moreover, alterations in the synthesis
of 15(S)-HETE have been also demonstrated in AERD
patients. This molecule is an intermediate metabolite of the
LXs pathway and is a potent chemoattractant for eosinophils
and neutrophils in the airways. Baseline levels of 15(S)-
HETE are increased in exhaled breath condensates from
AERD when compared to non-AERD subjects (53). Follow-
ing, in vitro stimulation of peripheral blood leukocytes with
aspirin, there is a generation of 15(S)-HETE only in AERD
subjects and this mechanism may be modulated by EP1 and
EP3 receptors and related to the expression of alternatively
spliced variants of COX-1 enzyme (54, 55). The mechanisms
regulating the synthesis of this metabolite in airways are not
known. However, we can speculate that some factors proba-
bly cell specific operating only in AERD patients determine
the release of free 15(S)-HETE instead of its usage in the
synthesis of ATLXs.
Taking altogether we can state that the balance between
pro- and anti-inflammatory eicosanoids is broken and plays a
crucial role in the development and chronicity of CRS as
shown in Fig. 2.
Staphylococcal SAgs
Superantigens are toxins of microbial or viral origin that
cross-link antigen-presenting cells (APCs) and T cells by
binding simultaneously to the major histocompatibility com-
plex class II (MHC-II) and the T-cell receptors (TCRs) (56).
They have an extreme ability to induce polyclonal activation
of CD4+ and CD8+ T cells and, in contrast to conventional
antigens, when presented on MHC-II, they are not processed
and presented as short peptides (56). The hallmark for T-cell
stimulation by SAgs is the specificity for the Vb part of the
T-cell receptor (TCR-Vb) (56). SAgs possess a specific TCR-
Vb profile that allows the expansion and activation of those
T cells bearing certain TCR-Vbs, while others will be
excluded (56). In addition, the TCR-Va subunit may interact
with the b-chain of MHC-II and the TCR-a chain and influ-
ence in this way the T-cell activation by the SAgs (56).
Staphylococcus aureus bacteria may secrete more than 10 dif-
ferent classical or egc-locus related enterotoxins (SEs), and
their production is tightly dependent of the bacterial strain
and host environment (57).
Staphylococcal SAgs and chronic sinus diseases
In the last decade, new evidences have raised supporting the
role of staphylococcal-derived enterotoxins in the pathogene-
sis of chronic sinus diseases (58–61) For the first time, Bac-
hert et al. (4) demonstrated the presence of specific IgE to
S. aureus enterotoxins in nasal polyp tissue, which correlated
with the severity of eosinophilic inflammation and the pres-
ence of asthma. Later, the same group demonstrated an
increase in polyclonal IgE and the formation of a secondary
© 2012 John Wiley & Sons A/S
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lymphoid tissue in nasal polyps from CRSwNP patients
associated with the presence of specific IgE-SEs and eosino-
philic inflammation (62), suggesting the occurrence of a
polyclonal B-cell activation because of the chronic microbial
colonization and release of enterotoxins (62). Additionally,
high total serum IgE and IgE-SEs levels have been observed
in patients with allergic rhinitis, which also manifested
sensitization to SEs (63).
Based on the previous studies, Corriveau et al. (64) dem-
onstrated an intramucosal colonization of the S. aureus
bacteria and detected that this was higher among CRSwNP
patients vs healthy subjects and CRSsNP. However, the
amount of bacteria found in the tissue did not correlate
with the amplification of the TH2-related inflammation
found in the CRSwNP patients, suggesting that the forma-
tion of specific IgE-SEs rather than the bacterial coloniza-
tion may be the crucial factor amplifying the inflammatory
pattern in these patients. Ex vivo studies have confirmed
that SEs mediate mast cell degranulation by binding to the
IgE high-affinity receptor (FceR1b) (60, 65). Short incuba-
tion (30 min) of nasal polyp tissue with staphylococcal
surface protein A induced mast cell degranulation charac-
terized by the production of histamine, CysLTs, and PGD2
(65) On the other hand, long stimulation (24 h) with staph-
ylococcal enterotoxin B (SEB) resulted in a significant
increase in cytokines with a TH2-skewed pattern in
nasal polyp tissue (65). Huvenne et al. (66) showed that
stimulation of human nasal epithelial cells with SEB
induced the up-regulation of pro-inflammatory mediators
resulting in an increase in neutrophil chemotaxis and
prolonged survival of eosinophilic granulocytes. These find-
ings contribute to the understanding of SEs modulation of
airway diseases.
Staphylococcal SAgs and AERD
Within the CRSwNP group, AERD patients have a 87.5%
colonization rate of S. aureus in the nasal mucosa (67). It
was also confirmed that nasal polyp tissue of patients with
AERD contains increased concentrations of total IgE and
IgE-SEs when compared to their non-AERD counterparts
and inferior turbinate tissue from healthy subjects (68). In
that study, 54% of patients within the AERD group and
26% from the non-AERD showed detectable levels of IgE-
SEs irrespective of the allergy status. However, a direct
correlation between eosinophilic activation markers and IgE-
SEs was only observed between patients with and those with-
out SE immune responses in the non-AERD group. Further,
Lee et al. (69) confirmed that the prevalence of specific IgE
to SEB and TSST-1 is significantly higher in asthmatic
patients compared to healthy controls, although no signifi-
cant differences could be found between AERD and non-
AERD subjects. Airway hyper-responsiveness was also sig-
nificantly increased in asthma patients with detectable
specific IgE-SEs compared to asthma patients without (69).
In a recent study, we could demonstrate that stimulation of
peripheral blood mononuclear cells with SEB significantly
increased TH1 and TH2 pro-inflammatory cytokines in both
Figure 2 Balance of eicosanoid biosynthesis in chronic rhinosinus-
itis (CRS) compared to healthy nasal mucosa. CRSsNP, chronic rhi-
nosinusitis without nasal polyps; CRSwNP, chronic rhinosinusitis
with nasal polyps; CRSwNP-AERD, chronic rhinosinusitis with nasal
polyps and aspirin-exacerbated respiratory disease. The magnitude
of the changes are represented by the shape of the arrows:
dashed arrows (less pronounced), solid arrows (most pronounced).
AERD, aspirin-exacerbated respiratory disease.
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AERD and non-AERD groups compared to controls (70).
This response may be related to a baseline deficiency of
Foxp3 and/or to the up-regulation of the tumor necrosis
factor receptor superfamily member 18 (TNFRS18-L) on
monocytes/dendritic cell precursors observed in the NP-
asthmatic patients regardless of the clinical occurrence of
AERD (70).
The data underline that staphylococcal SAgs contribute
to airway inflammation in both upper and lower airways
by influencing a large number of molecular inflammatory
mechanisms as shown in Fig. 3; however, there are no
arguments yet for a specific role of SEs in AERD.
Staphylococcal SAgs and eicosanoid metabolism
There is only little evidence that staphylococcal enterotox-
ins may influence eicosanoid biosynthesis in humans. In
1995, Mehindate et al. (71) showed that triggering of the
MHC-II by SEs in human fibroblast-like synoviocytes
induced the expression of extracellular matrix complex–
Figure 3 Effect of staphylococcal enterotoxins (SEs), IgE against
staphylococcal enterotoxins (IgE-SEs), and eicosanoid release on
the inflammatory network in upper airway diseases. (1) Binding of
SEs to MHC-II in antigen-presenting cells (APCs) and to the TCR
on T cells results in the activation of both TH1 and TH2 cells. (2)
TH2 cytokine IL-5 induces eosinophil activation and survival. Activa-
tion of eosinophils leads to the release of RANTES, eotaxin, LTB4,
and CysLTs (LTC4/D4/E4/). RANTES and eotaxin are potent chemo-
attractants and contribute to the further recruitment of eosinophils
and neutrophils to the inflamed tissue. CysLTs are potent eosino-
phil activators and greatly contribute to the release of eosinophil
cationic protein, chemokines, and hence CysLTs (autocrine loop)
contributing to chronic cell activation. (3) LTB4 is an important
chemoattractant and activator of neutrophils, which can also inter-
act and contribute to eosinophilic inflammation. (4) At the same
time, mast cells may be activated by local IgE-SEs resulting in their
degranulation and release of PGD2 and CysLTs promoting TH2 acti-
vation and recruitment and eosinophil inflammation. (5) TH1 cyto-
kine IFN-c has the capacity to induce the expression of MHC-II
molecules in nasal tissue fibroblasts. This allows SEs to bind to
these cells and blocks COX-2 and PGE2 production, cell growth
and increase cell migration influencing in this way tissue remodel-
ing. (6) Finally, the activation of nasal epithelial cells (SEs may be
one of the triggers) leads to the production of LXA4, which attenu-
ates neutrophil activation and recruitment, but also may induce
changes in Ca2+/Cl channels promoting edema. From the same
pathway, epithelial cells can also release 15-(S)-HETE, which pro-
motes neutrophil recruitment and activation. COX, cyclooxygenase-
1; 15-(S)-HETE, 15-Hydroxyeicosatetraenoic acid; SEs, Staphylococ-
cus aureus enterotoxins
© 2012 John Wiley & Sons A/S
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related molecules and this event was mediated by the
induction of COX-2 enzyme and the subsequent production
of PGE2. Later, Yamamura et al. (72) demonstrated that
synovial fibroblasts can function as accessory cells for SAg-
induced T-cell activation by influencing the synthesis of
stromelysin, IL-6, IL-8, and PGE2. This capacity of SEs to
regulate fibroblast function by acting via MHC-II was later
extrapolated to the upper airways. We demonstrated that
incubation of nasal tissue fibroblasts with the TH1 cytokine
IFN-c induced the expression of MHC-II molecules allow-
ing SEs bind to the cells. This resulted in a significant
down-regulation of PGE2 production, COX-2 and EP2
mRNA expression and influenced cell growth and migra-
tion (Fig. 3), which may contribute to the exacerbation of
inflammation in the nasal mucosa by mainly affecting tis-
sue remodeling (73). This may be explained by the fact that
with the down-regulation of PGE2, the potential of inhibit-
ing the pro-inflammatory effect of SEB as demonstrated by
Okano et al. decreases (74). In this study, SEB stimulation
of dispersed nasal polyp cells resulted in a significant
increase in IL-5, IL-13, RANTES cytokine production, and
eosinophil number, which was abolished after the adminis-
tration of PGE2 via an EP2 receptor– and EP4 receptor–
mediated mechanism (74). Furthermore, in 2001, Wehner
et al. (75) showed that stimulation of basophils from
patients with atopic eczema with SEs resulted in the release
of histamine and LTs, indicating a role of these toxins as
possible allergens in this group of patients. So far, there is
no evidence that SEs can directly influence the LTs regula-
tory pathway in the airways. However, these enterotoxins
can induce the synthesis of IL-5, which may induce the
activation of ALOX5 leading to CysLTs synthesis and
hence to the recruitment of activated eosinophils to the site
of inflammation (43). In upper airways, concentrations of
CysLTs, LTB4, and LXA4 are up-regulated and correlated
with the markers of eosinophil activation and survival
(ECP and IL-5) in nasal polyp tissue from patients exhibit-
ing an immune response to S. aureus enterotoxins as
compared with tissue from those who were negative for
IgE-SEs (18).
Conclusion
Chronic rhinosinusitis is considered a multifactorial disease
involving several immunological mechanisms that may act on
their own or in combination. In the last years, evidence has been
collected demonstrating the role of an imbalance in the synthesis
of eicosanoids in the development and chronicity of the disease.
This imbalance is based on a tissue cell deficiency in the produc-
tion of anti-inflammatory molecules such as prostaglandin E2
and lipoxins in contrast to high levels of pro-inflammatory
mediators such as CysLTs, prostaglandin D2, and 15-HETE.
This imbalance leads to a severe eosinophil inflammation and
changes in the cellular electrophysiology contributing to airway
hyper-responsiveness mainly observed in patients with CRS and
nasal polyps, and even more aggravated in asthmatic and aspi-
rin-intolerant patients. Furthermore, staphylococcal enterotox-
ins have gained special attention as amplifying factors of airway
inflammation. These molecules influence the local T-helper
immune response in nasal polyp patients and have been consid-
ered a determinant factor associated with severe disease. Still
extensive studies have to be carried out in order to elucidate the
mechanism regulating eicosanoid and immune response to SAgs
in airway diseases. However, they are currently considered a
major target for new diagnostic and therapeutic approaches,
which may have relevant clinical and economic implications.
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